Literature DB >> 36100476

Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal.

José Miguel Neves1, Nélia Cunha2, André Lencastre2, Joana Cabete2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 36100476      PMCID： PMC9582881          DOI： 10.1016/j.abd.2021.12.004

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN： 0365-0596            Impact factor:   2.113


× No keyword cloud information.
  10 in total

Review 1.  Management of patients with hidradenitis suppurativa.

Authors:  A Martorell; A Caballero; Y González Lama; D Jiménez-Gallo; M Lázaro Serrano; J Miranda; J C Pascual; L Salgado-Boquete; I Marín-Jiménez
Journal:  Actas Dermosifiliogr       Date:  2016-09

2.  Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.

Authors:  V Bettoli; M Manfredini; G Calamo; R Forconi; D Bencivelli; L Mantovani; G Pellacani; M Corazza
Journal:  Dermatol Ther       Date:  2018-10-08       Impact factor: 2.851

Review 3.  Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.

Authors:  Melody Maarouf; Ashley K Clark; Dylan E Lee; Vivian Y Shi
Journal:  J Dermatolog Treat       Date:  2017-11-10       Impact factor: 3.359

4.  Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.

Authors:  Amit Garg; Erica Neuren; Denny Cha; Joslyn S Kirby; John R Ingram; Gregor B E Jemec; Solveig Esmann; Linnea Thorlacius; Bente Villumsen; Véronique Del Marmol; Aude Nassif; Maia Delage; Thrasyvoulos Tzellos; Dagfinn Moseng; Øystein Grimstad; Haley Naik; Robert Micheletti; Sandra Guilbault; Angie Parks Miller; Iltefat Hamzavi; Hessel van der Zee; Errol Prens; Naomi Kappe; Christine Ardon; Brian Kirby; Rosalind Hughes; Christos C Zouboulis; Georgios Nikolakis; Falk G Bechara; Lukasz Matusiak; Jacek Szepietowski; Amelia Glowaczewska; Saxon D Smith; Noah Goldfarb; Steven Daveluy; Christina Avgoustou; Evangelos Giamarellos-Bourboulis; Steven Cohen; Yssra Soliman; Elena Gonzalez Brant; Oleg Akilov; Christopher Sayed; Jerry Tan; Afsaneh Alavi; Michelle A Lowes; José Carlos Pascual; Hassan Riad; Shani Fisher; Arnon Cohen; So Yeon Paek; Barry Resnik; Qiang Ju; Lanqi Wang; Andrew Strunk
Journal:  J Am Acad Dermatol       Date:  2019-07-03       Impact factor: 11.527

5.  Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.

Authors:  Christos C Zouboulis; Martin M Okun; Errol P Prens; Robert Gniadecki; Peter A Foley; Charles Lynde; Jamie Weisman; Yihua Gu; David A Williams; Gregor B E Jemec
Journal:  J Am Acad Dermatol       Date:  2018-06-01       Impact factor: 11.527

6.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Authors:  Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec
Journal:  N Engl J Med       Date:  2016-08-04       Impact factor: 91.245

Review 7.  Hidradenitis Suppurativa: Advances in Diagnosis and Treatment.

Authors:  Ditte Marie Lindhardt Saunte; Gregor Borut Ernst Jemec
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

8.  Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.

Authors:  C C Zouboulis; F G Bechara; J L Dickinson-Blok; W Gulliver; B Horváth; R Hughes; A B Kimball; B Kirby; A Martorell; M Podda; E P Prens; H C Ring; T Tzellos; H H van der Zee; K R van Straalen; A R J V Vossen; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-10-23       Impact factor: 6.166

9.  Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.

Authors:  G B E Jemec; M M Okun; S B Forman; W P F Gulliver; E P Prens; U Mrowietz; A W Armstrong; Z Geng; Y Gu; D A Williams; H D Teixeira; A B Kimball
Journal:  Br J Dermatol       Date:  2019-08-14       Impact factor: 9.302

10.  Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.

Authors:  A V Marzano; G Genovese; G Casazza; C Moltrasio; P Dapavo; G Micali; R Sirna; P Gisondi; A Patrizi; V Dini; D Bianchini; L Bianchi; L Fania; F Prignano; A Offidani; L Atzori; V Bettoli; S P Cannavò; M Venturini; M R Bongiorno; A Costanzo; G Fabbrocini; K Peris
Journal:  Br J Dermatol       Date:  2020-04-13       Impact factor: 9.302
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.